18.7% Average Loss With Semaglutide 7.2 mg at 72 Weeks
STEP UP compared a weekly 7.2 mg semaglutide regimen with 2.4 mg and placebo in adults with obesity without diabetes. Its 72-week results describe dose-specific trial averages under a defined protocol—not an individual outcome forecast or evidence that every provider offers the studied dose.
At week 72, mean body-weight change was −18.7% with semaglutide 7.2 mg, −15.6% with 2.4 mg, and −3.9% with placebo.
The estimated treatment difference was −14.8 percentage points versus placebo and −3.1 percentage points versus 2.4 mg. Gastrointestinal adverse events occurred in 70.8% with 7.2 mg, 61.2% with 2.4 mg, and 42.8% with placebo.
Turn the study result into a better program comparison
If this higher-dose result prompts you to explore GLP-1 care, compare details the trial did not test: product availability, medication status, clinician access, titration support, public price terms, and enrollment conditions. These reviewed brands have category-matched GLP-1 offers; none participated in or is endorsed by this study.
From $49 – $129/mo · Editorial score 4.7/5
Featured value terms: semaglutide $49/mo or tirzepatide $89/mo with 12-month prepayment; $99/$129 month to month.
We may earn a commission through provider links. Matching affiliate offers and editorial priorities affect inclusion and suggested order in commercial guides. Scores are not clinical endorsements. Disclosure · Methodology
Study details
- Population
- 1,407 adults without diabetes and with BMI of at least 30; 1,005 received semaglutide 7.2 mg, 201 received 2.4 mg, and 201 received placebo
- Follow-up
- 72 weeks
- Treatment comparison
- Once-weekly subcutaneous semaglutide 7.2 mg compared with semaglutide 2.4 mg or placebo, with lifestyle intervention
- Study design
- Phase 3b, multicenter, double-blind, randomized, placebo- and active-controlled trial
A study result is not a personal treatment plan
This article does not determine whether a higher-dose semaglutide regimen is appropriate for an individual, what a provider can prescribe, or what an insurer will cover. The study did not compare online programs or pharmacies. Dose selection and product availability require a licensed clinician and current prescribing information.
Compare semaglutide and tirzepatide programsWhat this result does not show
- The 72-week trial does not establish durability of weight change or safety beyond that period, including after treatment discontinuation.
- It enrolled adults with BMI of at least 30 and excluded diabetes, so results do not directly apply outside those characteristics.
- The 5:1:1 allocation left smaller 2.4 mg and placebo groups, limiting precision for uncommon harms and some comparative safety differences.
- The prespecified outcomes were body weight and weight-loss thresholds, not cardiovascular events, mortality, provider quality, or affordability.
- Novo Nordisk funded the trial; related affiliations and disclosures appear in the peer-reviewed article.
Related Studies
Explore other peer-reviewed results in Evidence Watch before comparing programs or discussing options with a clinician.
Primary peer-reviewed source
Read the full paper, methodology, conflict-of-interest disclosures, and supplementary materials before drawing conclusions beyond this plain-English summary.
Read the study at The Lancet Diabetes & Endocrinology